Feasibility, efficacy and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for hepatobiliary and pancreatic cancers with peritoneal metastases: A systematic review.
Eur J Surg OncolJul 8, 2026 (epub)
Henrique Silva Martins, Paula Rebelo, Jorge Nogueiro et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the feasibility, efficacy, and safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in 332 adult patients with hepatobiliary and pancreatic cancers with peritoneal metastases. The procedure was feasible, with non-access rates between 0% and 11.8%, and median overall survival ranged from 85 days to 15.1 months for hepatobiliary cancers and 8.5 to 12.7 months for pancreatic cancers.
Key findings
- PIPAC was feasible, with non-access rates ranging from 0% to 11.8%.
- Patients completed a mean of 1.3-1.8 cycles for hepatobiliary and 2.1-3 cycles for pancreatic cancers.
- Median overall survival for hepatobiliary malignancies ranged from 85 days to 15.1 months.
- No severe postoperative systemic toxicities (grade ≥3) were reported.
Why it matters
Understanding the feasibility and safety of PIPAC is crucial for clinicians managing patients with HPB cancers and peritoneal metastases, as it may offer a new therapeutic option in a challenging clinical scenario.